Press Release Summary:
Built for benchtop use, BD FACSMelody™ System identifies and isolates target cells for up to 9 colors. BD FACSChorus™ software guides researchers throughout entire cell sorting process using advanced automation technology. Researchers can simultaneously isolate 2 cell populations into separate tubes or deposit single or multiple target cells into 96- or 384-well plates. With BD FACSMelody system, researchers at multiple skill levelsÂ can achieve high-purity sorting.
Original Press Release:
BD Expands its Portfolio of Easy-to-Use Cell Sorters with Introduction of BD FACSMelody(TM) System
First Live Demonstration of the New Cell Sorter at Upcoming CYTO Annual Meeting
FRANKLIN LAKES, N.J., -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, continues to reinforce its commitment to making flow cytometry easier and more affordable with the introduction of its newest cell sorter, the BD FACSMelody((TM) )system. Built for benchtop use, the new BD FACSMelody sorter is easy to learn, install and use and provides excellent sensitivity, resolution and sort purity. The simplicity of the BD FACSMelody follows in the footsteps of other newly launched BD flow cytometers such as the BD Accuri((TM)) C6 Plus and BD FACSCelesta((TM)) systems.
The BD FACSMelody cell sorter features high sensitivity to identify and isolate target cells for up to nine colors, extending the multicolor capability compared to similar cell sorters that is essential for identification of dim or rare subpopulations. The new BD FACSChorus((TM)) software guides researchers throughout the entire cell sorting process using advanced automation technology. This cell sorting technology allows researchers to simultaneously isolate two cell populations into separate tubes or deposit single or multiple target cells into 96- or 384-well plates. The BD FACSMelody system enables researchers at multiple skill levels to achieve high-purity sorting.
"As a leader in cell analysis and sorting, BD's goal is to advance scientific discovery by providing expedient, high-performance cell isolation and sorting tools to a wide spectrum of researchers," said Claude Dartiguelongue, worldwide president of Biosciences for BD. "The BD FACSMelody system not only simplifies the entire operational process, but also has been designed to maximize cell population resolution and sort purity."
The BD FACSMelody cell sorting system is offered in six different configurations to best meet application needs ranging from a molecular biology lab isolating transfected cells with a single-color reporter gene to an immunology lab sorting a rare lymphocyte subset with a nine-color reagent panel. The system includes a gel-coupled cuvette, which eliminates optical fluidic alignment, provides excellent sensitivity and resolution, and is uniquely designed to leverage the broad BD Horizon Brilliant(TM) reagent portfolio. The BD FACSChorus software precisely regulates the sorting of droplets and steering of sorted cells into collection devices.
The first live presentation of the new BD FACSMelody cell sorter for research use only will be showcased in booth 318 during the upcoming CYTO annual meeting being held June 11-15 at the Washington State Convention Center. BD is now accepting purchase orders for the new BD FACSMelody sorter, and shipments will commence in the third quarter of this calendar year. For more information on the BD FACSMelody system, please visit bdbiosciences.com.
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.
BD Public Relations
Web Site: http://www.bd.com